[go: up one dir, main page]

MA40814A1 - Compositions pharmaceutiques pour thérapie combinée - Google Patents

Compositions pharmaceutiques pour thérapie combinée

Info

Publication number
MA40814A1
MA40814A1 MA40814A MA40814A MA40814A1 MA 40814 A1 MA40814 A1 MA 40814A1 MA 40814 A MA40814 A MA 40814A MA 40814 A MA40814 A MA 40814A MA 40814 A1 MA40814 A1 MA 40814A1
Authority
MA
Morocco
Prior art keywords
agonist
ppar
pharmaceutical compositions
combination therapy
combination
Prior art date
Application number
MA40814A
Other languages
English (en)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MA40814A1 publication Critical patent/MA40814A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant une combinaison d'un agoniste de fxr et au moins un agent réducteur de lipides (par exemple, agoniste de ppar-alpha agoniste de ppar-delta, agoniste de ppar-alpha et double delta et/ou statine). La présente invention concerne également l'utilisation de la combinaison pour le traitement ou la prévention d'une maladie ou affection à médiation par fxr, telle que la cirrhose biliaire primitive (pbc), la cholangite sclérosante primitive (
MA40814A 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée MA40814A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113134P 2015-02-06 2015-02-06
PCT/US2016/016694 WO2016127019A2 (fr) 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée

Publications (1)

Publication Number Publication Date
MA40814A1 true MA40814A1 (fr) 2019-08-30

Family

ID=56564878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40814A MA40814A1 (fr) 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée

Country Status (31)

Country Link
US (3) US11311557B2 (fr)
EP (2) EP3253382B1 (fr)
JP (2) JP7306791B2 (fr)
KR (1) KR20170115071A (fr)
CN (1) CN107405325B (fr)
AR (1) AR103624A1 (fr)
AU (2) AU2016215179B2 (fr)
BR (1) BR112017016766B1 (fr)
CA (1) CA2976056C (fr)
CL (3) CL2017001983A1 (fr)
CO (1) CO2017007959A2 (fr)
CR (1) CR20170356A (fr)
DK (1) DK3253382T3 (fr)
EA (1) EA036404B1 (fr)
EC (1) ECSP17057848A (fr)
ES (1) ES2905872T3 (fr)
GT (1) GT201700174A (fr)
HK (1) HK1246191A1 (fr)
IL (2) IL253719B (fr)
MA (1) MA40814A1 (fr)
MX (1) MX2017010131A (fr)
NI (1) NI201700100A (fr)
PE (1) PE20180027A1 (fr)
PH (1) PH12017501384A1 (fr)
SG (1) SG11201706347SA (fr)
SV (1) SV2017005512A (fr)
TN (1) TN2017000344A1 (fr)
TW (1) TW201628625A (fr)
UA (1) UA125744C2 (fr)
WO (1) WO2016127019A2 (fr)
ZA (1) ZA201706007B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
JP6879931B2 (ja) 2015-04-07 2021-06-02 インターセプト ファーマシューティカルズ， インコーポレイテッド 併用療法用の医薬組成物
AU2016325619A1 (en) 2015-09-24 2018-04-12 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
MX2021015783A (es) * 2016-03-31 2022-12-09 Genfit Metodos de tratamiento de enfermedades colestaticas.
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
EP3551180B1 (fr) * 2016-12-09 2021-09-29 Cadila Healthcare Limited Traitement de la cholangite biliaire primitive
CN110300580A (zh) * 2017-02-21 2019-10-01 基恩菲特公司 Ppar激动剂与fxr激动剂的组合
US20190076500A1 (en) * 2017-09-13 2019-03-14 Novartis Ag Combinations comprising fxr agonists
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
EP3952855A1 (fr) * 2019-04-10 2022-02-16 Genfit Polythérapie comprenant des composés de formule (i) et des agonistes du récepteur glp-1
CN114144185A (zh) * 2019-05-30 2022-03-04 英特塞普特医药品公司 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
CN110287493B (zh) * 2019-06-28 2023-04-18 中国科学技术信息研究所 风险短语识别方法、装置、电子设备及存储介质
CA3139291A1 (fr) * 2019-07-18 2021-01-21 Jacky Vonderscher Procede pour diminuer les effets secondaires de l'interferon
WO2021055725A1 (fr) * 2019-09-20 2021-03-25 Reneo Pharmaceuticals, Inc. Utilisation d'un agoniste ppar-delta dans le traitement de la maladie de dee
WO2021102251A1 (fr) * 2019-11-22 2021-05-27 Avolynt Utilisation d'inhibiteurs de sglt2 pour traiter la cholangite biliaire primitive
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN112885471B (zh) * 2021-03-12 2023-01-24 上海中医药大学附属岳阳中西医结合医院 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统
WO2023147141A1 (fr) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Polythérapie
WO2024132001A1 (fr) * 2022-12-21 2024-06-27 Charles University, Faculty Of Pharmacy In Hradec Kralove Ligands de récepteurs nucléaires multicibles à base d'acide 2-(4-(quinolin-2-yloxy)phénoxy)propanoïque et d'acide 2-(4-(quinoxalin-2-yloxy)phénoxy)propanoïque pour le traitement de maladies métaboliques et hépatiques

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (fr) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FI52570C (fi) 1969-04-16 1977-10-10 Sumitomo Chemical Co Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (fr) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (fr) 1973-07-05 1977-07-15 Roussel Uclaf
ES8101585A1 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE69329894T2 (de) 1992-12-08 2001-05-03 Ss Pharmaceutical Co., Ltd. Arylamidderivate
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP0001938A3 (en) 1997-01-24 2001-09-28 Univ California Use of fxr, pparalpha and lxralpha activators for producing pharmaceutical compositions useful for restoring barrier function, promoting epidermal differentiation and inhibiting proliferation
ID24275A (id) * 1997-08-29 2000-07-13 Pfizer Prod Inc Terapi kombinasi
KR100517644B1 (ko) 1997-10-27 2005-09-28 닥터 레디스 레보러터리즈 리미티드 신규의 삼원 화합물 및 그 약학적 용도, 그 제조방법 및이들을 포함하는 약제학적 조성물
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
EP1140036A2 (fr) 1998-12-18 2001-10-10 Abbott Laboratories Formulations comprenant des liporegulateurs
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
WO2000040965A1 (fr) 1999-01-07 2000-07-13 Tularik, Inc. Modulation du metabolisme du cholesterol induite par le recepteur fxr
US6071955A (en) 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
NZ522036A (en) 2000-04-19 2004-04-30 Borody Thomas J Compositions and therapies for hyperlipidaemia-associated disorders
WO2002020463A2 (fr) 2000-09-05 2002-03-14 Tularik Inc. Modulateurs fxr
ATE283253T1 (de) 2000-09-18 2004-12-15 Glaxo Group Ltd Substituierte aminopropoxyarylderivate als lxr agonisten
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
EP1285914B1 (fr) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Ligands du récepteur nucéaire nr1h4
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (fr) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Nouveau agonist steroidal pour FXR
GB0405349D0 (en) 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
SI2712617T1 (sl) 2004-03-12 2017-01-31 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo Fxr ligandov
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
BRPI0707794A2 (pt) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
CN101534641A (zh) * 2006-03-22 2009-09-16 哈佛大学校长及研究员协会 治疗高胆固醇血症和动脉粥样硬化的方法和组合物
CL2007001451A1 (es) 2006-05-24 2008-01-11 Eli Lilly And Company Soc Organizada Bajo Las Leyes Del Estado De Indiana Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas.
MX2008014854A (es) 2006-05-24 2008-12-05 Lilly Co Eli Antagonistas de fxr.
EP2040713B1 (fr) * 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Dérivés de l'acide biliaire en tant que des ligands de fxr pour la prévention ou le traitement de maladies ou conditions médiées par le fxr
EP2047851A4 (fr) 2006-08-04 2009-09-23 Aska Pharm Co Ltd Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
EP1894924A1 (fr) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Composés hétérocycliques de liason du FXR
EP1894928A1 (fr) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Composes heterocycliques de liaison au fxr
WO2008039829A2 (fr) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Inhibiteurs de l'absorption de cholestérol de diphénylhétérocycle
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
EP2289883A1 (fr) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Nouveaux composés modulant l'activité du recepteur FXR (NR1H4)
CN102647982B (zh) * 2009-11-26 2014-10-15 基恩菲特公司 使用1,3-二苯基丙-2-烯-1-酮衍生物治疗肝脏疾患
JP2015521621A (ja) 2012-06-19 2015-07-30 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の調製、使用および固体形態
CN108250264A (zh) 2012-10-26 2018-07-06 英特塞普特医药品公司 制备胆汁酸衍生物的方法
PL3360882T3 (pl) * 2013-05-14 2021-10-25 Intercept Pharmaceuticals, Inc. 11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu X
US10077268B2 (en) * 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии

Also Published As

Publication number Publication date
CA2976056A1 (fr) 2016-08-11
EP4035665A1 (fr) 2022-08-03
CA2976056C (fr) 2024-02-06
US20220280534A1 (en) 2022-09-08
ZA201706007B (en) 2019-01-30
CL2018001006A1 (es) 2018-06-15
CN107405325B (zh) 2021-11-12
JP2022000483A (ja) 2022-01-04
BR112017016766A2 (pt) 2018-04-10
EA201791770A1 (ru) 2017-12-29
CL2018003604A1 (es) 2019-02-22
WO2016127019A2 (fr) 2016-08-11
IL253719A0 (en) 2017-09-28
TN2017000344A1 (en) 2019-01-16
IL290823A (en) 2022-04-01
CR20170356A (es) 2018-02-28
GT201700174A (es) 2018-11-13
DK3253382T3 (da) 2022-02-14
EP3253382A4 (fr) 2018-10-31
US20220280533A1 (en) 2022-09-08
EP3253382B1 (fr) 2021-11-17
JP7306791B2 (ja) 2023-07-11
JP2018504438A (ja) 2018-02-15
AU2021201015A1 (en) 2021-03-11
PE20180027A1 (es) 2018-01-09
KR20170115071A (ko) 2017-10-16
UA125744C2 (uk) 2022-06-01
AU2016215179A1 (en) 2017-08-24
NI201700100A (es) 2018-09-06
CN107405325A (zh) 2017-11-28
AU2016215179B2 (en) 2021-02-25
ECSP17057848A (es) 2017-10-31
PH12017501384A1 (en) 2018-01-08
WO2016127019A3 (fr) 2016-11-03
CL2017001983A1 (es) 2018-04-20
SG11201706347SA (en) 2017-09-28
ES2905872T3 (es) 2022-04-12
TW201628625A (zh) 2016-08-16
IL253719B (en) 2022-04-01
EP3253382A2 (fr) 2017-12-13
MX2017010131A (es) 2017-11-01
US20180008616A1 (en) 2018-01-11
CO2017007959A2 (es) 2017-10-31
HK1246191A1 (zh) 2018-09-07
US11311557B2 (en) 2022-04-26
AR103624A1 (es) 2017-05-24
SV2017005512A (es) 2018-06-12
EA036404B1 (ru) 2020-11-06
BR112017016766B1 (pt) 2023-11-07

Similar Documents

Publication Publication Date Title
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
WO2020106647A3 (fr) Polythérapie comprenant un inhibiteur de krasg12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA46990B1 (fr) Compositions glp-1 et ses utilisations
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA40290A1 (fr) Agents immunorégulateurs
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
WO2019032528A8 (fr) Inhibiteurs bicycliques d'histone désacétylase
MA39319A1 (fr) Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires
MA38699A1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA61742A1 (fr) Composition pharmaceutique aqueuse d'anticorps anti pd-1 prolgolimab et son utilisation
BR112018003392A2 (pt) composição farmacêutica compreendendo um inibidor da hmg-coa redutase e um inibidor eca
WO2019221177A9 (fr) Médicament prophylactique et/ou thérapeutique contre la dépendance
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA53977B1 (fr) Compositions stables du sémaglutide et leurs utilisations